预防性喹诺酮联合卡介苗灌注治疗非肌层浸润性膀胱癌临床影响的系统评价与Meta分析
该系统评价与Meta分析纳入5项研究(4项随机对照试验进入Meta分析,共445例患者,194例接受喹诺酮预防+卡介苗,251例单用卡介苗),评估预防性喹诺酮对卡介苗灌注相关毒性及疗效的影响。结果显示喹诺酮预防可降低≥2级和≥3级卡介苗相关毒性并提高诱导完成率,但12个月复发率和进展率无显著差异。
要点
- 喹诺酮预防组≥2级卡介苗相关毒性发生率40.8% vs 单用卡介苗组54.7%(RR 0.79,95%CI 0.67-0.94;p=0.006)。
- 喹诺酮预防组≥3级卡介苗相关毒性发生率25.3% vs 单用卡介苗组36.4%(RR 0.70,95%CI 0.50-0.98;p=0.04)。
- 喹诺酮预防组卡介苗诱导完成率83.0% vs 单用卡介苗组70.6%(RR 1.16,95%CI 1.01-1.34;p=0.04)。
核心结论
- 预防性喹诺酮联合辅助卡介苗治疗非肌层浸润性膀胱癌可减轻卡介苗相关毒性并提高诱导治疗完成率。
研究设计与样本
- 系统评价与Meta分析,检索MEDLINE、Embase和Cochrane对照试验中心注册库(2024年10月),纳入报告喹诺酮预防与无预防比较结局的前瞻性和回顾性研究。
- 系统评价纳入5项研究,其中4项随机对照试验进入Meta分析,1项非随机研究进入叙述性综述,共445例患者,194例接受喹诺酮预防+卡介苗,251例单用卡介苗。
- 采用随机效应Meta分析,使用加权均数差进行合并。
主要发现
- 喹诺酮预防组≥2级卡介苗相关毒性发生率40.8% vs 单用卡介苗组54.7%(RR 0.79,95%CI 0.67-0.94;p=0.006)。
- 喹诺酮预防组≥3级卡介苗相关毒性发生率25.3% vs 单用卡介苗组36.4%(RR 0.70,95%CI 0.50-0.98;p=0.04)。
- 喹诺酮预防组卡介苗诱导完成率83.0% vs 单用卡介苗组70.6%(RR 1.16,95%CI 1.01-1.34;p=0.04)。
- 12个月复发率喹诺酮预防组14.7% vs 单用卡介苗组19.4%(RR 0.76,95%CI 0.46-1.27;p=0.3),两组无显著差异。
- 进展率喹诺酮预防组4.5% vs 单用卡介苗组6.4%(RR 0.86,95%CI 0.09-8.25;p=0.9),两组无显著差异。
临床怎么用
- 原文结论认为,预防性喹诺酮联合辅助卡介苗治疗非肌层浸润性膀胱癌可减轻卡介苗相关毒性并提高诱导治疗完成率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Bacillus Calmette-Guérin (BCG) reduces disease recurrence and progression in intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC). BCG-associated adverse events during instillations are common, leading to treatment cessation. Prophylactic use of quinolones in conjunction with BCG instillations is one approach for reducing BCG-associated adverse events. Our aim was to delineate the clinical impact of quinolone prophylaxis (QP) in patients receiving adjuvant BCG instillations for NMIBC. METHODS: In October 2024, a systematic search of MEDLINE, Embase, and the Cochrane Central Register of controlled trials was performed. Prospective and retrospective studies reporting comparative outcomes for patients with and without QP during BCG instillations were included. Outcomes were reported in a binary fashion. Random-effects meta-analysis using the weighted mean difference was conducted. Primary outcomes for pooled analyses included BCG-associated toxicities, the completion rate for BCG induction, the likelihood of antituberculosis treatment, and disease recurrence and progression at 12 mo. KEY FINDINGS AND LIMITATIONS: The systematic review included five studies. Four randomised controlled trials were included in the meta-analysis, and one nonrandomised study was also included in the narrative review. The studies involved 445 patients, of whom 194 received QP + BCG and 251 received BCG alone. QP use was associated with lower incidence of class ≥2 (40.8% vs 54.7%; relative risk [RR] 0.79, 95% confidence interval [CI] 0.67-0.94; p = 0.006), and class ≥3 BCG-associated toxicities (25.3% vs 36.4%; RR 0.70, 95% CI 0.50-0.98; p = 0.04) and a higher completion rate for BCG induction (83.0% vs 70.6%; RR 1.16, 95% CI 1.01-1.34; p = 0.04). The 12-mo recurrence rates (14.7% vs 19.4%; RR 0.76, 95% CI 0.46-1.27; p = 0.3) and progression rates (4.5% vs 6.4%; RR 0.86, 95% CI 0.09-8.25; p = 0.9) did not significantly differ for QP + BCG versus BCG alone. CONCLUSIONS AND CLINICAL IMPLICATIONS: The use of QP with adjuvant BCG for NMIBC mitigated debilitating BCG-associated toxicities and improved the completion rate for BCG induction therapy.
引用
- Wong CH, Ko IC, Leung DK, et al. A Systematic Review and Meta-analysis of the Clinical Impact of Prophylactic Quinolones with Adjuvant Bacillus Calmette-Guérin Instillation for Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2025. PMID: 39880747. doi:10.1016/j.euo.2024.12.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。